After a pharma view on biosimilars was provided in our previous Expert View column, a legal perspective is provided by Nick Beckett, managing partner at CMS Beijing and global co-head of the firm's lifesciences sector group.
The global biosimilars market is expected to reach $10.9 billion by 2021, according to the Biosimilars Global Forecast.
Although biosimilar products represent a major opportunity for the pharmaceutical industry, compared to small molecule drugs, bringing these complex proteins to market can be a real challenge, as we explore below.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze